{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:49:08Z","timestamp":1790092148513,"version":"4.0.1"},"reference-count":282,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-023-08969-x","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T06:02:37Z","timestamp":1692597757000},"page":"251-276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Treatable Traits in Systemic Sclerosis"],"prefix":"10.1007","volume":"65","author":[{"given":"Francesco","family":"Amati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Bongiovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Tonutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Stainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mangiameli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"key":"8969_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390:1685\u20131699","journal-title":"Lancet"},{"key":"8969_CR2","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1093\/rheumatology\/keab190","volume":"60","author":"M Bairkdar","year":"2021","unstructured":"Bairkdar M, Rossides M, Westerlind H, Hesselstrand R, Arkema EV, Holmqvist M (2021) Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. Rheumatology 60:3121\u20133133","journal-title":"Rheumatology"},{"key":"8969_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08946-w","author":"I Cavazzana","year":"2022","unstructured":"Cavazzana I, Vojinovic T, Airo\u2019 P, Fredi M, Ceribelli A, Pedretti E, Lazzaroni MG, Garrafa E, Franceschini F (2022) Systemic sclerosis-specific antibodies: novel and classical biomarkers. Clin Rev Allergy Immunol. https:\/\/doi.org\/10.1007\/s12016-022-08946-w","journal-title":"Clin Rev Allergy Immunol"},{"key":"8969_CR4","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76:1327\u20131339","journal-title":"Ann Rheum Dis"},{"key":"8969_CR5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0140-6736(20)32652-0","volume":"397","author":"D Poddubnyy","year":"2021","unstructured":"Poddubnyy D (2021) Precision medicine in rheumatology: are we getting closer? Lancet 397:258\u2013259","journal-title":"Lancet"},{"key":"8969_CR6","doi-asserted-by":"publisher","first-page":"1802058","DOI":"10.1183\/13993003.02058-2018","volume":"53","author":"VM McDonald","year":"2019","unstructured":"McDonald VM, Fingleton J, Agusti A et al (2019) Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report. Eur Respir J 53:1802058","journal-title":"Eur Respir J"},{"issue":"23","key":"8969_CR7","first-page":"00002","volume":"S2213\u20132600","author":"F Amati","year":"2023","unstructured":"Amati F, Spagnolo P, Oldham JM et al (2023) Treatable traits in interstitial lung diseases: a call to action. Lancet Respir Med S2213\u20132600(23):00002\u201300004","journal-title":"Lancet Respir Med"},{"key":"8969_CR8","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMsb1503104","volume":"372","author":"JL Jameson","year":"2015","unstructured":"Jameson JL, Longo DL (2015) Precision medicine\u2013personalized, problematic, and promising. N Engl J Med 372:2229\u20132234","journal-title":"N Engl J Med"},{"key":"8969_CR9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1183\/13993003.01359-2015","volume":"47","author":"A Agusti","year":"2016","unstructured":"Agusti A, Bel E, Thomas M et al (2016) Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 47:410\u2013419","journal-title":"Eur Respir J"},{"key":"8969_CR10","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1513\/AnnalsATS.201806-362OC","volume":"15","author":"SA Guler","year":"2018","unstructured":"Guler SA, Winstone TA, Murphy D, Hague C, Soon J, Sulaiman N, Li KH, Dunne J, Wilcox PG, Ryerson CJ (2018) Does systemic sclerosis-associated interstitial lung disease burn out? Specific phenotypes of disease progression. Ann Am Thorac Soc 15:1427\u20131433","journal-title":"Ann Am Thorac Soc"},{"key":"8969_CR11","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(15)60693-6","volume":"385","author":"PG Woodruff","year":"2015","unstructured":"Woodruff PG, Agusti A, Roche N, Singh D, Martinez FJ (2015) Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet 385:1789\u20131798","journal-title":"Lancet"},{"key":"8969_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/thoraxjnl-2013-203602","volume":"69","author":"LEGW Vanfleteren","year":"2014","unstructured":"Vanfleteren LEGW, Kocks JWH, Stone IS et al (2014) Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? Thorax 69:72\u201379","journal-title":"Thorax"},{"key":"8969_CR13","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/thoraxjnl-2014-205507","volume":"69","author":"A Agusti","year":"2014","unstructured":"Agusti A (2014) The path to personalised medicine in COPD. Thorax 69:857\u2013864","journal-title":"Thorax"},{"key":"8969_CR14","doi-asserted-by":"publisher","first-page":"1901509","DOI":"10.1183\/13993003.01509-2019","volume":"55","author":"VM McDonald","year":"2020","unstructured":"McDonald VM, Clark VL, Cordova-Rivera L, Wark PAB, Baines KJ, Gibson PG (2020) Targeting treatable traits in severe asthma: a randomised controlled trial. Eur Respir J 55:1901509","journal-title":"Eur Respir J"},{"key":"8969_CR15","doi-asserted-by":"publisher","first-page":"6285","DOI":"10.1007\/s00330-020-06986-4","volume":"30","author":"AA Trusculescu","year":"2020","unstructured":"Trusculescu AA, Manolescu D, Tudorache E, Oancea C (2020) Deep learning in interstitial lung disease-how long until daily practice. Eur Radiol 30:6285\u20136292","journal-title":"Eur Radiol"},{"key":"8969_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S2213-2600(19)30059-1","volume":"7","author":"G Raghu","year":"2019","unstructured":"Raghu G, Flaherty KR, Lederer DJ et al (2019) Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. Lancet Respir Med 7:487\u2013496","journal-title":"Lancet Respir Med"},{"key":"8969_CR17","unstructured":"Darwin C (1857) Darwin project\u00a0(University of Cambridge; ).\u00a0https:\/\/www.darwinproject.ac.uk\/letter\/DCP-LETT-2130.xml#back-mark-Lfoot.f6."},{"key":"8969_CR18","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1126\/science.aat5956","volume":"359","author":"J Berg","year":"2018","unstructured":"Berg J (2018) Lumping and splitting. Science 359:1309","journal-title":"Science"},{"key":"8969_CR19","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0117-2017","volume":"27","author":"MA Kokosi","year":"2018","unstructured":"Kokosi MA, Margaritopoulos GA, Wells AU (2018) Personalised medicine in interstitial lung diseases: number 6 in the series \u201cPersonalised medicine in respiratory diseases\u201d Edited by Renaud Louis and Nicolas Roche. Eur Respir Rev 27:170117","journal-title":"Eur Respir Rev"},{"key":"8969_CR20","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","volume":"8","author":"A Perelas","year":"2020","unstructured":"Perelas A, Silver RM, Arrossi AV, Highland KB (2020) Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med 8:304\u2013320","journal-title":"Lancet Respir Med"},{"key":"8969_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13075-019-1839-5","volume":"21","author":"J Moxey","year":"2019","unstructured":"Moxey J, Huq M, Proudman S et al (2019) Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis. Arthritis Res Ther 21:57","journal-title":"Arthritis Res Ther"},{"key":"8969_CR22","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1093\/rheumatology\/kev204","volume":"54","author":"G De Luca","year":"2015","unstructured":"De Luca G, Bosello SL, Berardi G et al (2015) Tumour-associated antigens in systemic sclerosis patients with interstitial lung disease: association with lung involvement and cancer risk. Rheumatology (Oxford) 54:1991\u20131999","journal-title":"Rheumatology (Oxford)"},{"key":"8969_CR23","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/art.40815","volume":"71","author":"M Elhai","year":"2019","unstructured":"Elhai M, Hoffmann-Vold AM, Avouac J et al (2019) Performance of candidate serum biomarkers for systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol 71:972\u2013982","journal-title":"Arthritis Rheumatol"},{"key":"8969_CR24","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00296-020-04604-6","volume":"40","author":"A Kim","year":"2020","unstructured":"Kim A, Kim Y, Kim G-T, Ahn E, So MW, Sohn DH, Lee S-G (2020) Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as potential makers for digital ulcers and interstitial lung disease in patients with systemic sclerosis: cross-sectional analysis of data from a prospective cohort study. Rheumatol Int 40:1071\u20131079","journal-title":"Rheumatol Int"},{"key":"8969_CR25","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/1756-185X.12290","volume":"17","author":"A Olewicz-Gawlik","year":"2014","unstructured":"Olewicz-Gawlik A, Danczak-Pazdrowska A, Kuznar-Kaminska B, Gornowicz-Porowska J, Katulska K, Trzybulska D, Batura-Gabryel H, Silny W, Poplawski D, Hrycaj P (2014) Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis. Int J Rheum Dis 17:664\u2013670","journal-title":"Int J Rheum Dis"},{"key":"8969_CR26","doi-asserted-by":"publisher","first-page":"R166","DOI":"10.1186\/ar3486","volume":"13","author":"M-E Truchetet","year":"2011","unstructured":"Truchetet M-E, Brembilla NC, Montanari E, Allanore Y, Chizzolini C (2011) Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther 13:R166","journal-title":"Arthritis Res Ther"},{"key":"8969_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.825567","volume":"9","author":"AG Versace","year":"2022","unstructured":"Versace AG, Bitto A, Ioppolo C et al (2022) IL-13 and IL-33 serum levels are increased in systemic sclerosis patients with interstitial lung disease. Front Med (Lausanne) 9:825567","journal-title":"Front Med (Lausanne)"},{"key":"8969_CR28","doi-asserted-by":"publisher","first-page":"867","DOI":"10.7150\/ijms.70984","volume":"19","author":"A Corrado","year":"2022","unstructured":"Corrado A, Rotondo C, Sanpaolo ER, Altomare A, Maruotti N, Cici D, Cantatore FP (2022) 1,25OH-vitamin D3 and IL-17 inhibition modulate pro-fibrotic cytokines production in peripheral blood mononuclear cells of patients with systemic sclerosis. Int J Med Sci 19:867\u2013877","journal-title":"Int J Med Sci"},{"key":"8969_CR29","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.4049\/jimmunol.1201115","volume":"189","author":"CG Lee","year":"2012","unstructured":"Lee CG, Herzog EL, Ahangari F et al (2012) Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-\u03b21 signaling. J Immunol 189:2635\u20132644","journal-title":"J Immunol"},{"key":"8969_CR30","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1177\/23971983211036571","volume":"6","author":"S O\u2019Reilly","year":"2021","unstructured":"O\u2019Reilly S (2021) Circulating gremlin-1 is elevated in systemic sclerosis patients. J Scleroderma Relat Disord 6:286\u2013289","journal-title":"J Scleroderma Relat Disord"},{"key":"8969_CR31","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/jclinpath-2017-204656","volume":"71","author":"S Bosello","year":"2018","unstructured":"Bosello S, Basile U, De Lorenzis E et al (2018) Free light chains of immunoglobulins in patients with systemic sclerosis: correlations with lung involvement and inflammatory milieu. J Clin Pathol 71:620\u2013625","journal-title":"J Clin Pathol"},{"key":"8969_CR32","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3899\/jrheum.111423","volume":"39","author":"C Muangchan","year":"2012","unstructured":"Muangchan C, Pope JE (2012) Interleukin 6 in systemic sclerosis and potential implications for targeted therapy. J Rheumatol 39:1120\u20131124","journal-title":"J Rheumatol"},{"key":"8969_CR33","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1002\/art.41020","volume":"71","author":"ER Volkmann","year":"2019","unstructured":"Volkmann ER, Tashkin DP, Kuwana M et al (2019) Progression of interstitial lung disease in systemic sclerosis: the importance of pneumoproteins Krebs von den Lungen 6 and CCL18. Arthritis Rheumatol 71:2059\u20132067","journal-title":"Arthritis Rheumatol"},{"key":"8969_CR34","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/art.40171","volume":"69","author":"M Wu","year":"2017","unstructured":"Wu M, Baron M, Pedroza C et al (2017) CCL2 in the circulation predicts long-term progression of interstitial lung disease in patients with early systemic sclerosis: data from two independent cohorts. Arthritis Rheumatol 69:1871\u20131878","journal-title":"Arthritis Rheumatol"},{"key":"8969_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100140","volume":"1","author":"X Gao","year":"2020","unstructured":"Gao X, Jia G, Guttman A et al (2020) Osteopontin links myeloid activation and disease progression in systemic sclerosis. Cell Rep Med 1:100140","journal-title":"Cell Rep Med"},{"key":"8969_CR36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jbspin.2017.11.006","volume":"85","author":"G Laustriat","year":"2018","unstructured":"Laustriat G, Ruyssen-Witrand A, Constantin A, Barnetche T, Adoue D, Cantagrel A, Degbo\u00e9 Y (2018) Anti-citrullinated peptides antibodies in systemic sclerosis: meta-analysis of frequency and meaning. Joint Bone Spine 85:147\u2013153","journal-title":"Joint Bone Spine"},{"key":"8969_CR37","doi-asserted-by":"publisher","first-page":"E5102","DOI":"10.3390\/ijms21145102","volume":"21","author":"R Lande","year":"2020","unstructured":"Lande R, Mennella A, Palazzo R et al (2020) Anti-CXCL4 antibody reactivity is present in systemic sclerosis (SSc) and correlates with the SSc type I interferon signature. Int J Mol Sci 21:E5102","journal-title":"Int J Mol Sci"},{"key":"8969_CR38","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/annrheumdis-2011-200837","volume":"71","author":"M Manetti","year":"2012","unstructured":"Manetti M, Guiducci S, Romano E, Bellando-Randone S, Conforti ML, Ibba-Manneschi L, Matucci-Cerinic M (2012) Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. Ann Rheum Dis 71:1064\u20131072","journal-title":"Ann Rheum Dis"},{"key":"8969_CR39","doi-asserted-by":"crossref","unstructured":"Matsushita T, Kobayashi T, Mizumaki K, et al (2018) BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance. Sci Adv 4:eaas9944","DOI":"10.1126\/sciadv.aas9944"},{"key":"8969_CR40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1365-2230.2007.02678.x","volume":"33","author":"K Komura","year":"2008","unstructured":"Komura K, Yanaba K, Ogawa F, Shimizu K, Takehara K, Sato S (2008) Elevation of IgG levels is a serological indicator for pulmonary fibrosis in systemic sclerosis with anti-topoisomerase I antibodies and those with anticentromere antibody. Clin Exp Dermatol 33:329\u2013332","journal-title":"Clin Exp Dermatol"},{"key":"8969_CR41","doi-asserted-by":"crossref","unstructured":"Shirai T, Suzuki J, Kuniyoshi S, Tanno Y, Fujii H (2022) Granulomatosis with polyangiitis following Pfizer-BioNTech COVID-19 vaccination. Mod Rheumatol Case Rep rxac016","DOI":"10.1093\/mrcr\/rxac016"},{"key":"8969_CR42","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/resp.13988","volume":"26","author":"CJW Stock","year":"2021","unstructured":"Stock CJW, Hoyles RK, Daccord C et al (2021) Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression. Respirology 26:461\u2013468","journal-title":"Respirology"},{"key":"8969_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206545","volume":"13","author":"A-M Hoffmann-Vold","year":"2018","unstructured":"Hoffmann-Vold A-M, Weigt SS, Palchevskiy V et al (2018) Augmented concentrations of CX3CL1 are associated with interstitial lung disease in systemic sclerosis. PLoS ONE 13:e0206545","journal-title":"PLoS ONE"},{"key":"8969_CR44","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s13075-016-1203-y","volume":"18","author":"ER Volkmann","year":"2016","unstructured":"Volkmann ER, Tashkin DP, Roth MD et al (2016) Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. Arthritis Res Ther 18:305","journal-title":"Arthritis Res Ther"},{"key":"8969_CR45","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/1346-8138.14538","volume":"45","author":"A Kuzumi","year":"2018","unstructured":"Kuzumi A, Yoshizaki A, Toyama S et al (2018) Serum interleukin-34 levels in patients with systemic sclerosis: clinical association with interstitial lung disease. J Dermatol 45:1216\u20131220","journal-title":"J Dermatol"},{"key":"8969_CR46","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.rbr.2015.04.001","volume":"56","author":"A Olewicz-Gawlik","year":"2016","unstructured":"Olewicz-Gawlik A, Trzybulska D, Kuznar-Kaminska B, Katulska K, Danczak-Pazdrowska A, Batura-Gabryel H, Hrycaj P (2016) Serum Clara cell 16-kDa protein levels and lung impairment in systemic sclerosis patients. Rev Bras Reumatol Engl Ed 56:309\u2013313","journal-title":"Rev Bras Reumatol Engl Ed"},{"key":"8969_CR47","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3899\/jrheum.170440","volume":"45","author":"S Rivi\u00e8re","year":"2018","unstructured":"Rivi\u00e8re S, Hua-Huy T, Tiev KP, Cabane J, Dinh-Xuan AT (2018) High baseline serum Clara cell 16 kDa predicts subsequent lung disease worsening in systemic sclerosis. J Rheumatol 45:242\u2013247","journal-title":"J Rheumatol"},{"key":"8969_CR48","doi-asserted-by":"publisher","first-page":"10882","DOI":"10.1038\/s41598-021-90333-0","volume":"11","author":"J Guiot","year":"2021","unstructured":"Guiot J, Njock M-S, Andr\u00e9 B, Gester F, Henket M, de Seny D, Moermans C, Malaise MG, Louis R (2021) Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction. Sci Rep 11:10882","journal-title":"Sci Rep"},{"key":"8969_CR49","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1164\/rccm.2106012","volume":"165","author":"D Bouros","year":"2002","unstructured":"Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, Haslam PL, Vassilakis DA, Black CM, du Bois RM (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165:1581\u20131586","journal-title":"Am J Respir Crit Care Med"},{"key":"8969_CR50","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1148\/radiol.2322031223","volume":"232","author":"SR Desai","year":"2004","unstructured":"Desai SR, Veeraraghavan S, Hansell DM et al (2004) CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 232:560\u2013567","journal-title":"Radiology"},{"key":"8969_CR51","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.21037\/jtd-20-2596","volume":"13","author":"K Kase","year":"2021","unstructured":"Kase K, Watanabe S, Saeki K et al (2021) Fractional analysis of bronchoalveolar lavage in systemic sclerosis-associated interstitial lung disease. J Thorac Dis 13:4146\u20134155","journal-title":"J Thorac Dis"},{"key":"8969_CR52","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/art.1780400422","volume":"40","author":"MB Bolster","year":"1997","unstructured":"Bolster MB, Ludwicka A, Sutherland SE, Strange C, Silver RM (1997) Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 40:743\u2013751","journal-title":"Arthritis Rheum"},{"key":"8969_CR53","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1186\/ar2766","volume":"11","author":"K Schmidt","year":"2009","unstructured":"Schmidt K, Martinez-Gamboa L, Meier S, Witt C, Meisel C, Hanitsch LG, Becker MO, Huscher D, Burmester GR, Riemekasten G (2009) Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther 11:R111","journal-title":"Arthritis Res Ther"},{"key":"8969_CR54","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1136\/ard.2003.014019","volume":"63","author":"F Meloni","year":"2004","unstructured":"Meloni F, Caporali R, Bianco AM, Paschetto E, Morosini M, Fietta AM, Bobbio-Pallavicini F, Pozzi E, Montecucco C (2004) Cytokine profile of bronchoalveolar lavage in systemic sclerosis with interstitial lung disease: comparison with usual interstitial pneumonia. Ann Rheum Dis 63:892\u2013894","journal-title":"Ann Rheum Dis"},{"key":"8969_CR55","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655\u20132666","journal-title":"N Engl J Med"},{"key":"8969_CR56","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:708\u2013719","journal-title":"Lancet Respir Med"},{"key":"8969_CR57","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna D, Lin CJF, Furst DE et al (2020) Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 8:963\u2013974","journal-title":"Lancet Respir Med"},{"key":"8969_CR58","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3899\/jrheum.120725","volume":"40","author":"A De Lauretis","year":"2013","unstructured":"De Lauretis A, Sestini P, Pantelidis P et al (2013) Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 40:435\u2013446","journal-title":"J Rheumatol"},{"key":"8969_CR59","first-page":"274","volume":"36","author":"MO Becker","year":"2019","unstructured":"Becker MO, Radic M, Schmidt K, Huscher D, Riedlinger A, Michelfelder M, Meisel C, Ewert R, Burmester G-R, Riemekasten G (2019) Serum cytokines and their predictive value in pulmonary involvement of systemic sclerosis. Sarcoidosis Vasc Diffuse Lung Dis 36:274\u2013284","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"8969_CR60","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1465-9921-6-96","volume":"6","author":"M De Santis","year":"2005","unstructured":"De Santis M, Bosello S, La Torre G, Capuano A, Tolusso B, Pagliari G, Pistelli R, Danza FM, Zoli A, Ferraccioli G (2005) Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res 6:96","journal-title":"Respir Res"},{"key":"8969_CR61","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.autrev.2014.07.003","volume":"13","author":"A Lanteri","year":"2014","unstructured":"Lanteri A, Sobanski V, Langlois C et al (2014) Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity. Autoimmun Rev 13:974\u2013980","journal-title":"Autoimmun Rev"},{"key":"8969_CR62","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12079-009-0068-0","volume":"3","author":"SA Lund","year":"2009","unstructured":"Lund SA, Giachelli CM, Scatena M (2009) The role of osteopontin in inflammatory processes. J Cell Commun Signal 3:311\u2013322","journal-title":"J Cell Commun Signal"},{"key":"8969_CR63","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3109\/s10165-012-0755-1","volume":"23","author":"T Takahashi","year":"2013","unstructured":"Takahashi T, Asano Y, Akamata K et al (2013) Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis. Mod Rheumatol 23:884\u2013890","journal-title":"Mod Rheumatol"},{"key":"8969_CR64","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1136\/annrheumdis-2011-200657","volume":"71","author":"MD Santis","year":"2012","unstructured":"Santis MD, Bosello SL, Capoluongo E et al (2012) A vascular endothelial growth factor deficiency characterises scleroderma lung disease. Ann Rheum Dis 71:1461\u20131465","journal-title":"Ann Rheum Dis"},{"key":"8969_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13317-016-0077-y","volume":"7","author":"M De Santis","year":"2016","unstructured":"De Santis M, Ceribelli A, Cavaciocchi F, Crotti C, Massarotti M, Belloli L, Marasini B, Isailovic N, Generali E, Selmi C (2016) Nailfold videocapillaroscopy and serum VEGF levels in scleroderma are associated with internal organ involvement. Autoimmun Highlights 7:1\u20139","journal-title":"Autoimmun Highlights"},{"key":"8969_CR66","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0083-6729(03)01008-2","volume":"66","author":"MR Bubb","year":"2003","unstructured":"Bubb MR (2003) Thymosin beta 4 interactions. Vitam Horm 66:297\u2013316","journal-title":"Vitam Horm"},{"key":"8969_CR67","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1465-9921-12-22","volume":"12","author":"M De Santis","year":"2011","unstructured":"De Santis M, Inzitari R, Bosello SL et al (2011) \u03b2-Thymosins and interstitial lung disease: study of a scleroderma cohort with a one-year follow-up. Respir Res 12:22","journal-title":"Respir Res"},{"key":"8969_CR68","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/annrheumdis-2020-217230","volume":"80","author":"P Spagnolo","year":"2021","unstructured":"Spagnolo P, Distler O, Ryerson CJ, Tzouvelekis A, Lee JS, Bonella F, Bouros D, Hoffmann-Vold A-M, Crestani B, Matteson EL (2021) Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Ann Rheum Dis 80:143\u2013150","journal-title":"Ann Rheum Dis"},{"key":"8969_CR69","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1007\/s10067-020-05105-4","volume":"39","author":"L Vanaken","year":"2020","unstructured":"Vanaken L, Landini N, Lenaerts J, Claeys E, Lenaerts J, Wuyts WA, Verschakelen J, De Langhe E (2020) Progressive lung fibrosis and mortality can occur in early systemic sclerosis patients without pulmonary abnormalities at baseline assessment. Clin Rheumatol 39:3393\u20133400","journal-title":"Clin Rheumatol"},{"key":"8969_CR70","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L et al (2022) Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT Clinical practice guideline. Am J Respir Crit Care Med 205:e18\u2013e47","journal-title":"Am J Respir Crit Care Med"},{"key":"8969_CR71","unstructured":"Roth M (2022) Scleroderma Lung Study III (SLS III): Combining the anti-fibrotic effects of pirfenidone (PFD) with mycophenolate (MMF) for treating scleroderma-related interstitial lung disease. clinicaltrials.gov"},{"key":"8969_CR72","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/jalm\/jfab108","volume":"7","author":"M Basuita","year":"2022","unstructured":"Basuita M, Fidler LM (2022) Myositis antibodies and interstitial lung disease. J Appl Lab Med 7:240\u2013258","journal-title":"J Appl Lab Med"},{"key":"8969_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2020.100049","volume":"3","author":"A Ceribelli","year":"2020","unstructured":"Ceribelli A, Isailovic N, De Santis M, Gorlino C, Satoh M, Selmi C (2020) Autoantibodies as biomarkers for interstitial lung disease in idiopathic inflammatory myositis and systemic sclerosis: The case of anti-eIF2B antibodies. J Transl Autoimmun 3:100049","journal-title":"J Transl Autoimmun"},{"key":"8969_CR74","first-page":"1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A et al (2018) Rheumatoid arthritis Nat Rev Dis Primers 4:1\u201323","journal-title":"Rheumatoid arthritis Nat Rev Dis Primers"},{"key":"8969_CR75","doi-asserted-by":"crossref","unstructured":"Zhang T, Shen P, Duan C, Gao L (2021) KL-6 as an immunological biomarker predicts the severity, progression, acute exacerbation, and poor outcomes of interstitial lung disease: a systematic review and meta-analysis.\u00a0Front immunol\u00a012:","DOI":"10.3389\/fimmu.2021.745233"},{"key":"8969_CR76","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1046\/j.1365-2222.2000.00760.x","volume":"30","author":"B Broeckaert","year":"2000","unstructured":"Broeckaert B (2000) Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker. Clin Exp Allergy 30:469\u2013475","journal-title":"Clin Exp Allergy"},{"key":"8969_CR77","doi-asserted-by":"crossref","unstructured":"Silva-Cardoso SC, Tao W, Angiolilli C et al (2020) CXCL4 links inflammation and fibrosis by reprogramming monocyte-derived dendritic cells in vitro.\u00a0Front immunol 11:","DOI":"10.3389\/fimmu.2020.02149"},{"key":"8969_CR78","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","volume":"75","author":"Z Brkic","year":"2016","unstructured":"Brkic Z, van Bon L, Cossu M et al (2016) The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann Rheum Dis 75:1567\u20131573","journal-title":"Ann Rheum Dis"},{"key":"8969_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.595811","volume":"12","author":"E Valenzi","year":"2021","unstructured":"Valenzi E, Tabib T, Papazoglou A, Sembrat J, Trejo Bittar HE, Rojas M, Lafyatis R (2021) Disparate interferon signaling and shared aberrant basaloid cells in single-cell profiling of idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease. Front Immunol 12:595811","journal-title":"Front Immunol"},{"key":"8969_CR80","doi-asserted-by":"publisher","first-page":"16833","DOI":"10.1038\/s41598-017-17007-8","volume":"7","author":"Y Ishida","year":"2017","unstructured":"Ishida Y, Kimura A, Nosaka M, Kuninaka Y, Hemmi H, Sasaki I, Kaisho T, Mukaida N, Kondo T (2017) Essential involvement of the CX3CL1-CX3CR1 axis in bleomycin-induced pulmonary fibrosis via regulation of fibrocyte and M2 macrophage migration. Sci Rep 7:16833","journal-title":"Sci Rep"},{"key":"8969_CR81","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1365-2567.2011.03541.x","volume":"135","author":"IU Schraufstatter","year":"2012","unstructured":"Schraufstatter IU, Zhao M, Khaldoyanidi SK, DiScipio RG (2012) The chemokine CCL18 causes maturation of cultured monocytes to macrophages in the M2 spectrum. Immunology 135:287\u2013298","journal-title":"Immunology"},{"key":"8969_CR82","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41584-022-00864-7","volume":"18","author":"D Fang","year":"2022","unstructured":"Fang D, Chen B, Lescoat A, Khanna D, Mu R (2022) Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis. Nat Rev Rheumatol 18:683\u2013693","journal-title":"Nat Rev Rheumatol"},{"key":"8969_CR83","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/art.40358","volume":"70","author":"JK Gordon","year":"2018","unstructured":"Gordon JK, Martyanov V, Franks JM, Bernstein EJ, Szymonifka J, Magro C, Wildman HF, Wood TA, Whitfield ML, Spiera RF (2018) Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, Pilot Trial. Arthritis Rheumatol 70:308\u2013316","journal-title":"Arthritis Rheumatol"},{"key":"8969_CR84","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.DMIH2-0029-2016","author":"KC Carroll","year":"2016","unstructured":"Carroll KC, Adams LL (2016) Lower respiratory tract infections. Microbiol Spectr. https:\/\/doi.org\/10.1128\/microbiolspec.DMIH2-0029-2016","journal-title":"Microbiol Spectr"},{"key":"8969_CR85","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"HR Collard","year":"2016","unstructured":"Collard HR, Ryerson CJ, Corte TJ et al (2016) Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med 194:265\u2013275","journal-title":"Am J Respir Crit Care Med"},{"key":"8969_CR86","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1752-699X.2010.00228.x","volume":"6","author":"M De Santis","year":"2012","unstructured":"De Santis M, Bosello SL, Peluso G et al (2012) Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease. Clin Respir J 6:9\u201317","journal-title":"Clin Respir J"},{"key":"8969_CR87","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/rheumatology\/kex471","volume":"57","author":"R Hesselstrand","year":"2018","unstructured":"Hesselstrand R, Nagel J, Saxne T, Geborek P, Skattum L, Kapetanovic MC (2018) Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis. Rheumatology (Oxford) 57:625\u2013630","journal-title":"Rheumatology (Oxford)"},{"key":"8969_CR88","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/rheumatology\/kep440","volume":"49","author":"L Mouthon","year":"2010","unstructured":"Mouthon L, Mestre C, B\u00e9rezn\u00e9 A, Poiraudeau S, Marchand C, Guilpain P, Guillevin L, Launay O (2010) Low influenza vaccination rate among patients with systemic sclerosis. Rheumatology (Oxford) 49:600\u2013606","journal-title":"Rheumatology (Oxford)"},{"key":"8969_CR89","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3390\/vaccines10050801","volume":"10","author":"M De Santis","year":"2022","unstructured":"De Santis M, Motta F, Isailovic N et al (2022) Dose-dependent impairment of the immune response to the Moderna-1273 mRNA vaccine by mycophenolate mofetil in patients with rheumatic and autoimmune liver diseases. Vaccines (Basel) 10:801","journal-title":"Vaccines (Basel)"},{"key":"8969_CR90","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1093\/rheumatology\/keab223","volume":"60","author":"J Arnold","year":"2021","unstructured":"Arnold J, Winthrop K, Emery P (2021) COVID-19 vaccination and antirheumatic therapy. Rheumatology (Oxford) 60:3496\u20133502","journal-title":"Rheumatology (Oxford)"},{"key":"8969_CR91","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s10067-020-05353-4","volume":"40","author":"P Ostojic","year":"2021","unstructured":"Ostojic P, Vujovic M (2021) Prevalence and clinical correlates of small airway obstruction in patients with systemic sclerosis. Clin Rheumatol 40:1417\u20131422","journal-title":"Clin Rheumatol"},{"key":"8969_CR92","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000820","volume":"5","author":"A Ariani","year":"2019","unstructured":"Ariani A, Silva M, Bravi E et al (2019) Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis. RMD Open 5:e000820","journal-title":"RMD Open"},{"key":"8969_CR93","doi-asserted-by":"publisher","first-page":"147997312210893","DOI":"10.1177\/14799731221089319","volume":"19","author":"DC Sanchez-Ramirez","year":"2022","unstructured":"Sanchez-Ramirez DC, Kosowan L, Singer A (2022) Management of cough in patients with idiopathic interstitial lung diseases in primary care. Chron Respir Dis 19:14799731221089320","journal-title":"Chron Respir Dis"},{"key":"8969_CR94","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1111\/resp.13084","volume":"22","author":"JZ Cheng","year":"2017","unstructured":"Cheng JZ, Wilcox PG, Glaspole I, Corte TJ, Murphy D, Hague CJ, Ryerson CJ (2017) Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases. Respirology 22:1592\u20131597","journal-title":"Respirology"},{"key":"8969_CR95","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.chest.2016.11.052","volume":"151","author":"DP Tashkin","year":"2017","unstructured":"Tashkin DP, Volkmann ER, Tseng C-H et al (2017) Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease: results of scleroderma lung study II. Chest 151:813\u2013820","journal-title":"Chest"},{"key":"8969_CR96","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1164\/ajrccm.179.12.1167","volume":"179","author":"N Carlo-Stella","year":"2009","unstructured":"Carlo-Stella N, Belloli L, Barbera R, Gambaro C, Rando G, Malesci A, Marasini B (2009) Gastroesophageal reflux and lung disease in systemic sclerosis. Am J Respir Crit Care Med 179:1167\u20131167","journal-title":"Am J Respir Crit Care Med"},{"key":"8969_CR97","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1164\/rccm.200808-1359OC","volume":"179","author":"E Savarino","year":"2009","unstructured":"Savarino E, Bazzica M, Zentilin P et al (2009) Gastroesophageal reflux and pulmonary fibrosis in scleroderma. Am J Respir Crit Care Med 179:408\u2013413","journal-title":"Am J Respir Crit Care Med"},{"key":"8969_CR98","first-page":"389","volume":"77","author":"RBC de Souza","year":"2009","unstructured":"de Souza RBC, Borges CTL, Capelozzi VL, Parra ER, Jatene FB, Kavakama J, Kairalla RA, Bonf\u00e1 E (2009) Centrilobular fibrosis: an underrecognized pattern in systemic sclerosis. RES 77:389\u2013397","journal-title":"RES"},{"key":"8969_CR99","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.semarthrit.2010.03.002","volume":"40","author":"RB Christmann","year":"2010","unstructured":"Christmann RB, Wells AU, Capelozzi VL, Silver RM (2010) Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum 40:241\u2013249","journal-title":"Semin Arthritis Rheum"},{"key":"8969_CR100","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/TP.0b013e3182845f23","volume":"95","author":"PD Sottile","year":"2013","unstructured":"Sottile PD, Iturbe D, Katsumoto TR et al (2013) Outcomes in systemic sclerosis-related lung disease following lung transplantation. Transplantation 95:975\u2013980","journal-title":"Transplantation"},{"key":"8969_CR101","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1001\/archsurg.2011.216","volume":"146","author":"T Hoppo","year":"2011","unstructured":"Hoppo T, Jarido V, Pennathur A et al (2011) Antireflux surgery preserves lung function in patients with gastroesophageal reflux disease and end-stage lung disease before and after lung transplantation. Arch Surg 146:1041\u20131047","journal-title":"Arch Surg"},{"key":"8969_CR102","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11325-020-02080-7","volume":"25","author":"S Gundogdu","year":"2021","unstructured":"Gundogdu S, Borekci S, Atahan E, Musellim B (2021) Increased frequency of obstructive sleep apnea in the patients with systemic sclerosis. Sleep Breath 25:237\u2013242","journal-title":"Sleep Breath"},{"key":"8969_CR103","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/art.1780360405","volume":"36","author":"M Abu-Shakra","year":"1993","unstructured":"Abu-Shakra M, Guillemin F, Lee P (1993) Cancer in systemic sclerosis. Arthritis Rheum 36:460\u2013464","journal-title":"Arthritis Rheum"},{"key":"8969_CR104","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S2213-2600(17)30478-2","volume":"6","author":"A Tzouvelekis","year":"2018","unstructured":"Tzouvelekis A, Spagnolo P, Bonella F, Vancheri C, Tzilas V, Crestani B, Kreuter M, Bouros D (2018) Patients with IPF and lung cancer: diagnosis and management. Lancet Respir Med 6:86\u201388","journal-title":"Lancet Respir Med"},{"key":"8969_CR105","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/2397198318766825","volume":"3","author":"L Sakr","year":"2018","unstructured":"Sakr L, Hudson M, Wang M, Younanian E, Baron M, Bernatsky S (2018) Interstitial lung disease is associated with an increased risk of lung cancer in systemic sclerosis: Longitudinal data from the Canadian Scleroderma Research Group. J Scleroderma Relat Disord 3:221\u2013227","journal-title":"J Scleroderma Relat Disord"},{"key":"8969_CR106","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/rheumatology\/kes303","volume":"52","author":"M Bonifazi","year":"2013","unstructured":"Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento EV, La Vecchia C, Negri E, Gabrielli A (2013) Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 52:143\u2013154","journal-title":"Rheumatology (Oxford)"},{"key":"8969_CR107","doi-asserted-by":"publisher","first-page":"993","DOI":"10.4330\/wjc.v6.i9.993","volume":"6","author":"S Lambova","year":"2014","unstructured":"Lambova S (2014) Cardiac manifestations in systemic sclerosis. World J Cardiol 6:993\u20131005","journal-title":"World J Cardiol"},{"key":"8969_CR108","first-page":"272","volume":"6","author":"D Pattanaik","year":"2015","unstructured":"Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE (2015) Pathogenesis of systemic sclerosis Front Immunol 6:272","journal-title":"Pathogenesis of systemic sclerosis Front Immunol"},{"key":"8969_CR109","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00281-015-0505-5","volume":"37","author":"Y Asano","year":"2015","unstructured":"Asano Y, Sato S (2015) Vasculopathy in scleroderma. Semin Immunopathol 37:489\u2013500","journal-title":"Semin Immunopathol"},{"key":"8969_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2021.101668","volume":"35","author":"C Bruni","year":"2021","unstructured":"Bruni C, Ross L (2021) Cardiac involvement in systemic sclerosis: getting to the heart of the matter. Best Pract Res Clin Rheumatol 35:101668","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"8969_CR111","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/IBPC.S232038","volume":"13","author":"S Almaaitah","year":"2020","unstructured":"Almaaitah S, Highland KB, Tonelli AR (2020) Management of pulmonary arterial hypertension in patients with systemic sclerosis. Integr Blood Press Control 13:15\u201329","journal-title":"Integr Blood Press Control"},{"key":"8969_CR112","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1183\/09031936.00174914","volume":"45","author":"L Wollin","year":"2015","unstructured":"Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, Kolb M (2015) Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 45:1434\u20131445","journal-title":"Eur Respir J"},{"key":"8969_CR113","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.autrev.2017.05.024","volume":"16","author":"Y Mostmans","year":"2017","unstructured":"Mostmans Y, Cutolo M, Giddelo C et al (2017) The role of endothelial cells in the vasculopathy of systemic sclerosis: a systematic review. Autoimmun Rev 16:774\u2013786","journal-title":"Autoimmun Rev"},{"key":"8969_CR114","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/BOR.0000000000000112","volume":"26","author":"N Altorok","year":"2014","unstructured":"Altorok N, Wang Y, Kahaleh B (2014) Endothelial dysfunction in systemic sclerosis. Curr Opin Rheumatol 26:615\u2013620","journal-title":"Curr Opin Rheumatol"},{"key":"8969_CR115","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41584-020-0386-4","volume":"16","author":"M Hughes","year":"2020","unstructured":"Hughes M, Allanore Y, Chung L, Pauling JD, Denton CP, Matucci-Cerinic M (2020) Raynaud phenomenon and digital ulcers in systemic sclerosis. Nat Rev Rheumatol 16:208\u2013221","journal-title":"Nat Rev Rheumatol"},{"key":"8969_CR116","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/jcla.21864","volume":"30","author":"P B\u0103l\u0103nescu","year":"2016","unstructured":"B\u0103l\u0103nescu P, L\u0103daru A, B\u0103l\u0103nescu E, Voiosu T, B\u0103icu\u015f C, Dan GA (2016) Endocan, novel potential biomarker for systemic sclerosis: results of a pilot study. J Clin Lab Anal 30:368\u2013373","journal-title":"J Clin Lab Anal"},{"key":"8969_CR117","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s42358-020-00140-w","volume":"60","author":"AMC Horimoto","year":"2020","unstructured":"Horimoto AMC, de Jesus LG, de Souza AS, Rodrigues SH, Kayser C (2020) Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study. Adv Rheumatol 60:38","journal-title":"Adv Rheumatol"},{"key":"8969_CR118","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s43166-020-00025-2","volume":"47","author":"MY Mahgoub","year":"2020","unstructured":"Mahgoub MY, Fouda AI, Elshambaky AY, Elgazzar WB, Shalaby SA (2020) Validity of endocan as a biomarker in systemic sclerosis: relation to pathogenesis and disease activity. Egypt Rheumatol Rehabil 47:23","journal-title":"Egypt Rheumatol Rehabil"},{"key":"8969_CR119","first-page":"S48","volume":"28","author":"Y Allanore","year":"2010","unstructured":"Allanore Y, Meune C (2010) Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin. Clin Exp Rheumatol 28:S48-53","journal-title":"Clin Exp Rheumatol"},{"key":"8969_CR120","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/art.1780280607","volume":"28","author":"A Kahan","year":"1985","unstructured":"Kahan A, Nitenberg A, Foult JM, Amor B, Menkes CJ, Devaux JY, Blanchet F, Perennec J, Lutfalla G, Roucayrol JC (1985) Decreased coronary reserve in primary scleroderma myocardial disease. Arthritis Rheum 28:637\u2013646","journal-title":"Arthritis Rheum"},{"key":"8969_CR121","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(89)92088-6","volume":"2","author":"R Gustafsson","year":"1989","unstructured":"Gustafsson R, Mannting F, Kazzam E, Waldenstr\u00f6m A, H\u00e4llgren R (1989) Cold-induced reversible myocardial ischaemia in systemic sclerosis. Lancet 2:475\u2013479","journal-title":"Lancet"},{"key":"8969_CR122","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1136\/ard.2004.031484","volume":"64","author":"O Vignaux","year":"2005","unstructured":"Vignaux O, Allanore Y, Meune C, Pascal O, Duboc D, Weber S, Legmann P, Kahan A (2005) Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann Rheum Dis 64:1268\u20131273","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 100","key":"8969_CR123","first-page":"129","volume":"34","author":"V Thakkar","year":"2016","unstructured":"Thakkar V, Stevens W, Prior D et al (2016) The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study. Clin Exp Rheumatol 34(Suppl 100):129\u2013136","journal-title":"Clin Exp Rheumatol"},{"key":"8969_CR124","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3899\/jrheum.090931","volume":"37","author":"T Dimitroulas","year":"2010","unstructured":"Dimitroulas T, Giannakoulas G, Papadopoulou K, Karvounis H, Dimitroula H, Koliakos G, Karamitsos T, Parcharidou D, Settas L (2010) Early detection of cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography: relationship with neurohormonal activation and endothelial dysfunction. J Rheumatol 37:993\u2013999","journal-title":"J Rheumatol"},{"key":"8969_CR125","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1023\/A:1022422932108","volume":"244","author":"CM Rembold","year":"2003","unstructured":"Rembold CM, Ayers CR (2003) Oral L-arginine can reverse digital necrosis in Raynaud\u2019s phenomenon. Mol Cell Biochem 244:139\u2013141","journal-title":"Mol Cell Biochem"},{"key":"8969_CR126","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/jdv.15180","volume":"33","author":"P Curtiss","year":"2019","unstructured":"Curtiss P, Schwager Z, Lo Sicco K, Franks AG (2019) The clinical effects of l-arginine and asymmetric dimethylarginine: implications for treatment in secondary Raynaud\u2019s phenomenon. J Eur Acad Dermatol Venereol 33:497\u2013503","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"8969_CR127","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3899\/jrheum.131210","volume":"41","author":"L Mouthon","year":"2014","unstructured":"Mouthon L, Bussone G, Berezn\u00e9 A, No\u00ebl L-H, Guillevin L (2014) Scleroderma renal crisis. J Rheumatol 41:1040\u20131048","journal-title":"J Rheumatol"},{"key":"8969_CR128","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1159\/000507886","volume":"45","author":"M Chrabaszcz","year":"2020","unstructured":"Chrabaszcz M, Ma\u0142yszko J, Sikora M, Alda-Malicka R, Stochmal A, Matuszkiewicz-Rowinska J, Rudnicka L (2020) Renal involvement in systemic sclerosis: an update. Kidney Blood Press Res 45:532\u2013548","journal-title":"Kidney Blood Press Res"},{"key":"8969_CR129","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/543704","volume":"2010","author":"I Batal","year":"2010","unstructured":"Batal I, Domsic RT, Medsger TA, Bastacky S (2010) Scleroderma renal crisis: a pathology perspective. Int J Rheumatol 2010:543704","journal-title":"Int J Rheumatol"},{"key":"8969_CR130","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s13075-016-1168-x","volume":"18","author":"M Okr\u00f3j","year":"2016","unstructured":"Okr\u00f3j M, Johansson M, Saxne T, Blom AM, Hesselstrand R (2016) Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis. Arthritis Res Ther 18:267","journal-title":"Arthritis Res Ther"},{"key":"8969_CR131","first-page":"6051083","volume":"2018","author":"MH Uriarte","year":"2018","unstructured":"Uriarte MH, Larrarte C, Rey LB (2018) Scleroderma renal crisis debute with thrombotic microangiopathy: a successful case treated with eculizumab. Case Rep Nephrol 2018:6051083","journal-title":"Case Rep Nephrol"},{"key":"8969_CR132","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13075-017-1370-5","volume":"19","author":"M Matucci-Cerinic","year":"2017","unstructured":"Matucci-Cerinic M, Manetti M, Bruni C, Chora I, Bellando-Randone S, Lepri G, De Paulis A, Guiducci S (2017) The \u201cmyth\u201d of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event? Arthritis Res Ther 19:162","journal-title":"Arthritis Res Ther"},{"key":"8969_CR133","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3389\/fphys.2018.00587","volume":"9","author":"B Odler","year":"2018","unstructured":"Odler B, Foris V, Gungl A, M\u00fcller V, Hassoun PM, Kwapiszewska G, Olschewski H, Kovacs G (2018) Biomarkers for pulmonary vascular remodeling in systemic sclerosis: a pathophysiological approach. Front Physiol 9:587","journal-title":"Front Physiol"},{"key":"8969_CR134","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2174\/1573397114666180809121005","volume":"15","author":"VA Flower","year":"2019","unstructured":"Flower VA, Barratt SL, Ward S, Pauling JD (2019) The role of vascular endothelial growth factor in systemic sclerosis. Curr Rheumatol Rev 15:99\u2013109","journal-title":"Curr Rheumatol Rev"},{"issue":"Suppl 119","key":"8969_CR135","first-page":"158","volume":"37","author":"A Gigante","year":"2019","unstructured":"Gigante A, Galea N, Gasperini ML, Guarnera L, Carbone I, Rosato E (2019) Myocardial fibrosis in systemic sclerosis assessed by cardiac magnetic resonance is associated with vascular endothelial growth factor expression. Clin Exp Rheumatol 37(Suppl 119):158","journal-title":"Clin Exp Rheumatol"},{"key":"8969_CR136","doi-asserted-by":"crossref","unstructured":"Ninagawa K, Kato M, Tsuneta S, Ishizaka S, Ujiie H, Hisada R, Kono M, Fujieda Y, Ito YM, Atsumi T (2022) Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study. Rheumatology (Oxford) keac674","DOI":"10.1093\/rheumatology\/keac674"},{"key":"8969_CR137","doi-asserted-by":"publisher","first-page":"312","DOI":"10.4330\/wjc.v4.i12.312","volume":"4","author":"M Koutroumpi","year":"2012","unstructured":"Koutroumpi M, Dimopoulos S, Psarra K, Kyprianou T, Nanas S (2012) Circulating endothelial and progenitor cells: evidence from acute and long-term exercise effects. World J Cardiol 4:312\u2013326","journal-title":"World J Cardiol"},{"key":"8969_CR138","first-page":"421","volume":"26","author":"T Nevskaya","year":"2008","unstructured":"Nevskaya T, Bykovskaia S, Lyssuk E, Shakhov I, Zaprjagaeva M, Mach E, Ananieva L, Guseva N, Nassonov E (2008) Circulating endothelial progenitor cells in systemic sclerosis: relation to impaired angiogenesis and cardiovascular manifestations. Clin Exp Rheumatol 26:421\u2013429","journal-title":"Clin Exp Rheumatol"},{"key":"8969_CR139","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1002\/art.30536","volume":"63","author":"J Avouac","year":"2011","unstructured":"Avouac J, Cagnard N, Distler JH, Schoindre Y, Ruiz B, Couraud PO, Uzan G, Boileau C, Chiocchia G, Allanore Y (2011) Insights into the pathogenesis of systemic sclerosis based on the gene expression profile of progenitor-derived endothelial cells. Arthritis Rheum 63:3552\u20133562","journal-title":"Arthritis Rheum"},{"key":"8969_CR140","doi-asserted-by":"publisher","first-page":"R165","DOI":"10.1186\/ar4349","volume":"15","author":"M Manetti","year":"2013","unstructured":"Manetti M, Guiducci S, Romano E et al (2013) Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis. Arthritis Res Ther 15:R165","journal-title":"Arthritis Res Ther"},{"key":"8969_CR141","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12891-016-1197-2","volume":"17","author":"S Patschan","year":"2016","unstructured":"Patschan S, Tampe D, M\u00fcller C, Seitz C, Herink C, M\u00fcller GA, Zeisberg E, Zeisberg M, Henze E, Patschan D (2016) Early endothelial progenitor cells (eEPCs) in systemic sclerosis (SSc) - dynamics of cellular regeneration and mesenchymal transdifferentiation. BMC Musculoskelet Disord 17:339","journal-title":"BMC Musculoskelet Disord"},{"key":"8969_CR142","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.semarthrit.2015.10.013","volume":"45","author":"K Ladak","year":"2016","unstructured":"Ladak K, Pope JE (2016) A review of the effects of statins in systemic sclerosis. Semin Arthritis Rheum 45:698\u2013705","journal-title":"Semin Arthritis Rheum"},{"key":"8969_CR143","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1002\/art.21899","volume":"54","author":"M Kuwana","year":"2006","unstructured":"Kuwana M, Kaburaki J, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y (2006) Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum 54:1946\u20131951","journal-title":"Arthritis Rheum"},{"key":"8969_CR144","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3109\/s10165-009-0199-4","volume":"19","author":"M Kuwana","year":"2009","unstructured":"Kuwana M, Okazaki Y, Kaburaki J (2009) Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis. Mod Rheumatol 19:530\u2013535","journal-title":"Mod Rheumatol"},{"key":"8969_CR145","first-page":"1323","volume":"35","author":"N Del Papa","year":"2008","unstructured":"Del Papa N, Cortiana M, Vitali C, Silvestris I, Maglione W, Comina DP, Lucchi T, Cortelezzi A (2008) Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis. J Rheumatol 35:1323\u20131328","journal-title":"J Rheumatol"},{"key":"8969_CR146","volume":"145","author":"Huber LC, Bye H, Brock M, Swiss Society of Pulmonary Hypertension","year":"2015","unstructured":"Huber LC, Bye H, Brock M, Swiss Society of Pulmonary Hypertension (2015) The pathogenesis of pulmonary hypertension\u2013an update. Swiss Med Wkly 145:w14202","journal-title":"Swiss Med Wkly"},{"key":"8969_CR147","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","volume":"73","author":"JG Coghlan","year":"2014","unstructured":"Coghlan JG, Denton CP, Gr\u00fcnig E et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73:1340\u20131349","journal-title":"Ann Rheum Dis"},{"key":"8969_CR148","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2147\/VHRM.S4713","volume":"5","author":"CJ Valerio","year":"2009","unstructured":"Valerio CJ, Coghlan JG (2009) Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. Vasc Health Risk Manag 5:607\u2013619","journal-title":"Vasc Health Risk Manag"},{"key":"8969_CR149","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00005-014-0310-1","volume":"63","author":"A Kowalczyk","year":"2015","unstructured":"Kowalczyk A, Kleniewska P, Kolodziejczyk M, Skibska B, Goraca A (2015) The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis. Arch Immunol Ther Exp (Warsz) 63:41\u201352","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"8969_CR150","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10067-013-2354-8","volume":"33","author":"M Ciurzy\u0144ski","year":"2014","unstructured":"Ciurzy\u0144ski M, Bienias P, Irzyk K, Kostrubiec M, Bartoszewicz Z, Siwicka M, Stelmaszczyk-Emmel A, G\u00f3rska E, Demkow U, Pruszczyk P (2014) Serum endothelin-1 and NT-proBNP, but not ADMA, endoglin and TIMP-1 levels, reflect impaired right ventricular function in patients with systemic sclerosis. Clin Rheumatol 33:83\u201389","journal-title":"Clin Rheumatol"},{"key":"8969_CR151","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.2147\/DDDT.S103534","volume":"10","author":"EA Hardin","year":"2016","unstructured":"Hardin EA, Chin KM (2016) Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy. Drug Des Devel Ther 10:3747\u20133754","journal-title":"Drug Des Devel Ther"},{"key":"8969_CR152","doi-asserted-by":"crossref","unstructured":"Lemmers JM, Fretheim H, Knaapen HK, van den Hoogen FH, van Haren-Willems JH, Duijnhouwer AL, van Dijk AP, van den Ende CH, Hoffmann-Vold A-M, Vonk MC (2020) Selexipag treatment in patients with systemic sclerosis-associated pulmonary arterial hypertension in clinical practice, a case series. J Scleroderma Relat Disord 5:NP7\u2013NP11","DOI":"10.1177\/2397198320916082"},{"key":"8969_CR153","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4103\/2229-5178.93484","volume":"3","author":"M Aghaei","year":"2012","unstructured":"Aghaei M, Gharibdost F, Zayeni H, Akhlaghi M, Sedighi S, Rostamian AR, Aghdami N, Shojaa M (2012) Endothelin-1 in systemic sclerosis. Indian Dermatol Online J 3:14\u201316","journal-title":"Indian Dermatol Online J"},{"key":"8969_CR154","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/125632","volume":"2013","author":"E Cozzani","year":"2013","unstructured":"Cozzani E, Javor S, Laborai E, Drosera M, Parodi A (2013) Endothelin-1 levels in scleroderma patients: a pilot study. ISRN Dermatol 2013:125632","journal-title":"ISRN Dermatol"},{"key":"8969_CR155","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/ard.2010.130658","volume":"70","author":"M Matucci-Cerinic","year":"2011","unstructured":"Matucci-Cerinic M, Denton CP, Furst DE et al (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70:32\u201338","journal-title":"Ann Rheum Dis"},{"key":"8969_CR156","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1136\/thx.2004.029082","volume":"60","author":"MC Tamby","year":"2005","unstructured":"Tamby MC, Chanseaud Y, Humbert M et al (2005) Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax 60:765\u2013772","journal-title":"Thorax"},{"key":"8969_CR157","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1136\/ard.2008.102400","volume":"69","author":"C Mihai","year":"2010","unstructured":"Mihai C, Tervaert JWC (2010) Anti-endothelial cell antibodies in systemic sclerosis. Ann Rheum Dis 69:319\u2013324","journal-title":"Ann Rheum Dis"},{"key":"8969_CR158","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S0002-9343(96)00404-4","volume":"102","author":"KV Salojin","year":"1997","unstructured":"Salojin KV, Le Tonqu\u00e8ze M, Saraux A, Nassonov EL, Dueymes M, Piette JC, Youinou PY (1997) Antiendothelial cell antibodies: useful markers of systemic sclerosis. Am J Med 102:178\u2013185","journal-title":"Am J Med"},{"key":"8969_CR159","first-page":"462","volume":"25","author":"VS Negi","year":"1998","unstructured":"Negi VS, Tripathy NK, Misra R, Nityanand S (1998) Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 25:462\u2013466","journal-title":"J Rheumatol"},{"key":"8969_CR160","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s42358-021-00170-y","volume":"61","author":"MMV de Figueiredo Caldas","year":"2021","unstructured":"de Figueiredo Caldas MMV, de Azevedo KPM, de Fran\u00e7a Nunes AC, de Oliveira VH, Pimenta IDSF, de Ara\u00fajo IDT, Neto FAB, da Silveira Gon\u00e7alves de Oliveira AK, Piuvezam G (2021) Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis. Adv Rheumatol 61:15","journal-title":"Adv Rheumatol"},{"key":"8969_CR161","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/art.1780311209","volume":"31","author":"RM Marks","year":"1988","unstructured":"Marks RM, Czerniecki M, Andrews BS, Penny R (1988) The effects of scleroderma serum on human microvascular endothelial cells. Induction of antibody-dependent cellular cytotoxicity. Arthritis Rheum 31:1524\u20131534","journal-title":"Arthritis Rheum"},{"key":"8969_CR162","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1046\/j.1365-2249.1996.d01-867.x","volume":"106","author":"MB Hill","year":"1996","unstructured":"Hill MB, Phipps JL, Cartwright RJ, Milford Ward A, Greaves M, Hughes P (1996) Antibodies to membranes of endothelial cells and fibroblasts in scleroderma. Clin Exp Immunol 106:491\u2013497","journal-title":"Clin Exp Immunol"},{"key":"8969_CR163","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001039","volume":"26","author":"DJ Theodorou","year":"2020","unstructured":"Theodorou DJ, Theodorou SJ, Rizos D, Tzimas T (2020) Myocarditis in scleroderma: an underrecognized manifestation of the disease. J Clin Rheumatol 26:e146","journal-title":"J Clin Rheumatol"},{"key":"8969_CR164","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/ehf2.12139","volume":"4","author":"AR Ramalho","year":"2017","unstructured":"Ramalho AR, Costa S, Silva F, Donato P, Franco F, P\u00eago GM (2017) Autoimmune myocarditis in systemic sclerosis: an unusual form of scleroderma heart disease presentation. ESC Heart Fail 4:365\u2013370","journal-title":"ESC Heart Fail"},{"key":"8969_CR165","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.jacc.2020.01.036","volume":"75","author":"G Peretto","year":"2020","unstructured":"Peretto G, Sala S, Rizzo S et al (2020) Ventricular arrhythmias in myocarditis: characterization and relationships with myocardial inflammation. J Am Coll Cardiol 75:1046\u20131057","journal-title":"J Am Coll Cardiol"},{"key":"8969_CR166","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.semarthrit.2013.07.006","volume":"43","author":"M Pieroni","year":"2014","unstructured":"Pieroni M, De Santis M, Zizzo G et al (2014) Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. Semin Arthritis Rheum 43:526\u2013535","journal-title":"Semin Arthritis Rheum"},{"key":"8969_CR167","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2021-220044","volume":"82","author":"MD Santis","year":"2023","unstructured":"Santis MD, Tonutti A, Motta F, Rodolfi S, Monti L, Francone M, Selmi C (2023) Pos1284 myocardial involvement characterizes early systemic sclerosis with anti-Scl70 antibodies and longstanding disease with anti-centromere antibodies. Ann Rheum Dis 82:988\u2013989","journal-title":"Ann Rheum Dis"},{"key":"8969_CR168","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1161\/CIRCIMAGING.113.000416","volume":"6","author":"MG Friedrich","year":"2013","unstructured":"Friedrich MG, Marcotte F (2013) Cardiac magnetic resonance assessment of myocarditis. Circ Cardiovasc Imaging 6:833\u2013839","journal-title":"Circ Cardiovasc Imaging"},{"key":"8969_CR169","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653950","volume":"12","author":"G De Luca","year":"2021","unstructured":"De Luca G, Cavalli G, Campochiaro C, Bruni C, Tomelleri A, Dagna L, Matucci-Cerinic M (2021) Interleukin-1 and systemic sclerosis: getting to the heart of cardiac involvement. Front Immunol 12:653950","journal-title":"Front Immunol"},{"key":"8969_CR170","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.675678","volume":"12","author":"E Della-Torre","year":"2021","unstructured":"Della-Torre E, Lanzillotta M, Campochiaro C et al (2021) Respiratory impairment predicts response to IL-1 and IL-6 blockade in COVID-19 patients with severe pneumonia and hyper-inflammation. Front Immunol 12:675678","journal-title":"Front Immunol"},{"key":"8969_CR171","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","volume":"72","author":"VM Ferreira","year":"2018","unstructured":"Ferreira VM, Schulz-Menger J, Holmvang G et al (2018) Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 72:3158\u20133176","journal-title":"J Am Coll Cardiol"},{"key":"8969_CR172","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/BOR.0000000000000645","volume":"31","author":"ZH McMahan","year":"2019","unstructured":"McMahan ZH (2019) Gastrointestinal involvement in systemic sclerosis: an update. Curr Opin Rheumatol 31:561\u2013568","journal-title":"Curr Opin Rheumatol"},{"key":"8969_CR173","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1007\/s00296-011-1988-6","volume":"32","author":"T Schmeiser","year":"2012","unstructured":"Schmeiser T, Saar P, Jin D et al (2012) Profile of gastrointestinal involvement in patients with systemic sclerosis. Rheumatol Int 32:2471\u20132478","journal-title":"Rheumatol Int"},{"key":"8969_CR174","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/rheumatology\/key350","volume":"58","author":"Richard N, Hudson M, Wang M, Gyger G, Proudman S, Stevens W, Nikpour M, Canadian Scleroderma Research Group (CSRG), Australian Scleroderma Interest Group (ASIG), Baron M","year":"2019","unstructured":"Richard N, Hudson M, Wang M, Gyger G, Proudman S, Stevens W, Nikpour M, Canadian Scleroderma Research Group (CSRG), Australian Scleroderma Interest Group (ASIG), Baron M (2019) Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. Rheumatology (Oxford) 58:636\u2013644","journal-title":"Rheumatology (Oxford)"},{"key":"8969_CR175","doi-asserted-by":"publisher","first-page":"6201","DOI":"10.12998\/wjcc.v9.i22.6201","volume":"9","author":"A Luquez-Mindiola","year":"2021","unstructured":"Luquez-Mindiola A, Atuesta AJ, G\u00f3mez-Aldana AJ (2021) Gastrointestinal manifestations of systemic sclerosis: an updated review. World J Clin Cases 9:6201\u20136217","journal-title":"World J Clin Cases"},{"key":"8969_CR176","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163894","volume":"11","author":"VK Jaeger","year":"2016","unstructured":"Jaeger VK, Wirz EG, Allanore Y et al (2016) Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS ONE 11:e0163894","journal-title":"PLoS ONE"},{"key":"8969_CR177","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1007\/s10620-018-4977-8","volume":"63","author":"LI Sakkas","year":"2018","unstructured":"Sakkas LI, Simopoulou T, Daoussis D, Liossis S-N, Potamianos S (2018) Intestinal involvement in systemic sclerosis: a clinical review. Dig Dis Sci 63:834\u2013844","journal-title":"Dig Dis Sci"},{"key":"8969_CR178","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/acr.23763","volume":"71","author":"ZH McMahan","year":"2019","unstructured":"McMahan ZH, Domsic RT, Zhu L, Medsger TA, Casciola-Rosen L, Shah AA (2019) Anti-RNPC-3 (U11\/U12) antibodies in systemic sclerosis in patients with moderate-to-severe gastrointestinal dysmotility. Arthritis Care Res (Hoboken) 71:1164\u20131170","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8969_CR179","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1007\/s10067-020-05479-5","volume":"40","author":"Y Suliman","year":"2021","unstructured":"Suliman Y, Kafaja S, Oh SJ et al (2021) Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SSc cohorts. Clin Rheumatol 40:2277\u20132284","journal-title":"Clin Rheumatol"},{"key":"8969_CR180","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1365-2796.2010.02340.x","volume":"270","author":"K Andr\u00e9asson","year":"2011","unstructured":"Andr\u00e9asson K, Scheja A, Saxne T, Ohlsson B, Hesselstrand R (2011) Faecal calprotectin: a biomarker of gastrointestinal disease in systemic sclerosis. J Intern Med 270:50\u201357","journal-title":"J Intern Med"},{"key":"8969_CR181","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cps.2019.08.016","volume":"47","author":"A Daumas","year":"2020","unstructured":"Daumas A, Magalon J, Delaunay F, Abellan M, Philandrianos C, Sabatier F, Granel B, Magalon G (2020) Fat grafting for treatment of facial scleroderma. Clin Plast Surg 47:155\u2013163","journal-title":"Clin Plast Surg"},{"key":"8969_CR182","first-page":"1997","volume":"12","author":"A Berl","year":"2022","unstructured":"Berl A, Shir-Az O, Perk N, Levy A, Levy Y, Shalom A (2022) Total facial autologous fat grafting for treating skin manifestations in scleroderma. Life (Basel) 12:1997","journal-title":"Life (Basel)"},{"key":"8969_CR183","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1089\/ten.tea.2009.0635","volume":"16","author":"S Merfeld-Clauss","year":"2010","unstructured":"Merfeld-Clauss S, Gollahalli N, March KL, Traktuev DO (2010) Adipose tissue progenitor cells directly interact with endothelial cells to induce vascular network formation. Tissue Eng Part A 16:2953\u20132966","journal-title":"Tissue Eng Part A"},{"key":"8969_CR184","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41584-022-00900-6","volume":"19","author":"ZH McMahan","year":"2023","unstructured":"McMahan ZH, Kulkarni S, Chen J, Chen JZ, Xavier RJ, Pasricha PJ, Khanna D (2023) Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management. Nat Rev Rheumatol 19:166\u2013181","journal-title":"Nat Rev Rheumatol"},{"key":"8969_CR185","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1136\/gut.2005.086074","volume":"55","author":"CGP Roberts","year":"2006","unstructured":"Roberts CGP, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM (2006) A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut 55:1697\u20131703","journal-title":"Gut"},{"key":"8969_CR186","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/0002-9343(69)90044-8","volume":"46","author":"WA D\u2019Angelo","year":"1969","unstructured":"D\u2019Angelo WA, Fries JF, Masi AT, Shulman LE (1969) Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 46:428\u2013440","journal-title":"Am J Med"},{"key":"8969_CR187","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/apt.12818","volume":"40","author":"I Marie","year":"2014","unstructured":"Marie I, Antonietti M, Houivet E et al (2014) Gastrointestinal mucosal abnormalities using videocapsule endoscopy in systemic sclerosis. Aliment Pharmacol Ther 40:189\u2013199","journal-title":"Aliment Pharmacol Ther"},{"key":"8969_CR188","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/00004836-200108000-00017","volume":"33","author":"D Singh","year":"2001","unstructured":"Singh D, Shill M, Kaur H (2001) The watermelon rectum. J Clin Gastroenterol 33:164\u2013166","journal-title":"J Clin Gastroenterol"},{"key":"8969_CR189","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/2397198319891282","volume":"6","author":"A-M Hoffmann-Vold","year":"2021","unstructured":"Hoffmann-Vold A-M, Volkmann ER (2021) Gastrointestinal involvement in systemic sclerosis: effects on morbidity and mortality and new therapeutic approaches. J Scleroderma Relat Disord 6:37\u201343","journal-title":"J Scleroderma Relat Disord"},{"key":"8969_CR190","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13075-022-02790-1","volume":"24","author":"K Morrisroe","year":"2022","unstructured":"Morrisroe K, Hansen D, Stevens W, Sahhar J, Ngian G-S, Hill C, Roddy J, Walker J, Proudman S, Nikpour M (2022) Gastric antral vascular ectasia in systemic sclerosis: a study of its epidemiology, disease characteristics and impact on survival. Arthritis Res Ther 24:103","journal-title":"Arthritis Res Ther"},{"key":"8969_CR191","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/RHU.0000000000000927","volume":"26","author":"APL Assad","year":"2020","unstructured":"Assad APL, Farias R, Gaspari CN, da Silva HC, Andrade DCO, Sampaio-Barros PD (2020) Diagnosis and management of gastric antral vascular ectasia: experience in a large single cohort of patients with systemic sclerosis. J Clin Rheumatol 26:79\u201381","journal-title":"J Clin Rheumatol"},{"key":"8969_CR192","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.14309\/ajg.0000000000000397","volume":"114","author":"JB Brandler","year":"2019","unstructured":"Brandler JB, Sweetser S, Khoshbin K, Babameto M, Prokop LJ, Camilleri M (2019) Colonic manifestations and complications are relatively under-reported in systemic sclerosis: a systematic review. Am J Gastroenterol 114:1847\u20131856","journal-title":"Am J Gastroenterol"},{"key":"8969_CR193","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.5152\/eurjrheum.2019.19103","volume":"7","author":"ER Volkmann","year":"2020","unstructured":"Volkmann ER, Hoffmann-Vold A-M (2020) Gastrointestinal tract microbiota modifications in systemic sclerosis. Eur J Rheumatol 7:S228\u2013S236","journal-title":"Eur J Rheumatol"},{"key":"8969_CR194","unstructured":"Volkmann ER (2022) Is there a role for the microbiome in systemic sclerosis? Expert Rev Clin Immunol 1\u20135"},{"key":"8969_CR195","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/acr2.11387","volume":"4","author":"K Andr\u00e9asson","year":"2022","unstructured":"Andr\u00e9asson K, Lee SM, Lagishetty V, Wu M, Howlett N, English J, Hesselstrand R, Clements PJ, Jacobs JP, Volkmann ER (2022) Disease features and gastrointestinal microbial composition in patients with systemic sclerosis from two independent cohorts. ACR Open Rheumatol 4:417\u2013425","journal-title":"ACR Open Rheumatol"},{"key":"8969_CR196","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3390\/ijms23020977","volume":"23","author":"F Amati","year":"2022","unstructured":"Amati F, Stainer A, Mantero M et al (2022) Lung microbiome in idiopathic pulmonary fibrosis and other interstitial lung diseases. Int J Mol Sci 23:977","journal-title":"Int J Mol Sci"},{"key":"8969_CR197","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2017-000134","volume":"4","author":"ER Volkmann","year":"2017","unstructured":"Volkmann ER, Hoffmann-Vold A-M, Chang Y-L et al (2017) Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. BMJ Open Gastroenterol 4:e000134","journal-title":"BMJ Open Gastroenterol"},{"key":"8969_CR198","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13075-016-1182-z","volume":"18","author":"K Andr\u00e9asson","year":"2016","unstructured":"Andr\u00e9asson K, Alrawi Z, Persson A, J\u00f6nsson G, Marsal J (2016) Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease. Arthritis Res Ther 18:278","journal-title":"Arthritis Res Ther"},{"key":"8969_CR199","doi-asserted-by":"publisher","first-page":"14874","DOI":"10.1038\/s41598-017-14889-6","volume":"7","author":"V Patrone","year":"2017","unstructured":"Patrone V, Puglisi E, Cardinali M, Schnitzler TS, Svegliati S, Festa A, Gabrielli A, Morelli L (2017) Gut microbiota profile in systemic sclerosis patients with and without clinical evidence of gastrointestinal involvement. Sci Rep 7:14874","journal-title":"Sci Rep"},{"key":"8969_CR200","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/nyas.13736","volume":"1421","author":"C Bellocchi","year":"2018","unstructured":"Bellocchi C, Fern\u00e1ndez-Ochoa \u00c1, Montanelli G et al (2018) Microbial and metabolic multi-omic correlations in systemic sclerosis patients. Ann N Y Acad Sci 1421:97\u2013109","journal-title":"Ann N Y Acad Sci"},{"key":"8969_CR201","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/diagnostics10080587","volume":"10","author":"B Polkowska-Pruszy\u0144ska","year":"2020","unstructured":"Polkowska-Pruszy\u0144ska B, Gerkowicz A, Rawicz-Pruszy\u0144ski K, Krasowska D (2020) The role of fecal calprotectin in patients with systemic sclerosis and small intestinal bacterial overgrowth (SIBO). Diagnostics (Basel) 10:587","journal-title":"Diagnostics (Basel)"},{"key":"8969_CR202","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.semarthrit.2012.09.004","volume":"42","author":"L Gemignani","year":"2013","unstructured":"Gemignani L, Savarino V, Ghio M et al (2013) Lactulose breath test to assess oro-cecal transit delay and estimate esophageal dysmotility in scleroderma patients. Semin Arthritis Rheum 42:522\u2013529","journal-title":"Semin Arthritis Rheum"},{"key":"8969_CR203","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s10067-020-05446-0","volume":"40","author":"B Ebrahimi","year":"2021","unstructured":"Ebrahimi B, Nazarinia M, Molayem M (2021) Calprotectin, an available prognostic biomarker in systemic sclerosis: a systematic review. Clin Rheumatol 40:1709\u20131715","journal-title":"Clin Rheumatol"},{"key":"8969_CR204","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.autrev.2015.01.018","volume":"14","author":"I Marie","year":"2015","unstructured":"Marie I, Leroi A-M, Menard J-F, Levesque H, Quillard M, Ducrotte P (2015) Fecal calprotectin in systemic sclerosis and review of the literature. Autoimmun Rev 14:547\u2013554","journal-title":"Autoimmun Rev"},{"key":"8969_CR205","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00296-010-1595-y","volume":"32","author":"R Thonhofer","year":"2012","unstructured":"Thonhofer R, Siegel C, Trummer M, Graninger W (2012) Early endoscopy in systemic sclerosis without gastrointestinal symptoms. Rheumatol Int 32:165\u2013168","journal-title":"Rheumatol Int"},{"key":"8969_CR206","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nrgastro.2018.7","volume":"15","author":"J Keller","year":"2018","unstructured":"Keller J, Bassotti G, Clarke J et al (2018) Expert consensus document: advances in the diagnosis and classification of gastric and intestinal motility disorders. Nat Rev Gastroenterol Hepatol 15:291\u2013308","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8969_CR207","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13075-017-1340-y","volume":"19","author":"B Vigone","year":"2017","unstructured":"Vigone B, Caronni M, Severino A, Bellocchi C, Baldassarri AR, Fraquelli M, Montanelli G, Santaniello A, Beretta L (2017) Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. Arthritis Res Ther 19:145","journal-title":"Arthritis Res Ther"},{"key":"8969_CR208","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/RHU.0b013e3180645d2a","volume":"13","author":"GC Nikou","year":"2007","unstructured":"Nikou GC, Toumpanakis C, Katsiari C, Charalambopoulos D, Sfikakis PP (2007) Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients. J Clin Rheumatol 13:119\u2013123","journal-title":"J Clin Rheumatol"},{"key":"8969_CR209","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.3899\/jrheum.090694","volume":"36","author":"Baron M, Hudson M, Steele R, Canadian Scleroderma Research Group","year":"2009","unstructured":"Baron M, Hudson M, Steele R, Canadian Scleroderma Research Group (2009) Malnutrition is common in systemic sclerosis: results from the Canadian scleroderma research group database. J Rheumatol 36:2737\u20132743","journal-title":"J Rheumatol"},{"key":"8969_CR210","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1136\/ard.2009.123273","volume":"69","author":"L Krause","year":"2010","unstructured":"Krause L, Becker MO, Brueckner CS et al (2010) Nutritional status as marker for disease activity and severity predicting mortality in patients with systemic sclerosis. Ann Rheum Dis 69:1951\u20131957","journal-title":"Ann Rheum Dis"},{"key":"8969_CR211","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2169\/internalmedicine.1431-18","volume":"58","author":"Y Matsumoto","year":"2019","unstructured":"Matsumoto Y, Hayashi H, Tahara K, Yasuda T, Tsubouchi S, Yamamoto Y, Mizuuchi T, Mori H, Sawada T (2019) Intravenous cyclophosphamide for gastric antral vascular ectasia associated with systemic sclerosis refractory to endoscopic treatment: a case report and review of the pertinent literature. Intern Med 58:135\u2013139","journal-title":"Intern Med"},{"key":"8969_CR212","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3899\/jrheum.141234","volume":"42","author":"A Bhattacharyya","year":"2015","unstructured":"Bhattacharyya A, Sahhar J, Milliken S, Ma D, Englert H, Tymms K, Danta M, Moore J (2015) Autologous hematopoietic stem cell transplant for systemic sclerosis improves anemia from gastric antral vascular ectasia. J Rheumatol 42:554\u2013555","journal-title":"J Rheumatol"},{"key":"8969_CR213","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/rheumatology\/36.2.280","volume":"36","author":"O Ortiz-Alvarez","year":"1997","unstructured":"Ortiz-Alvarez O, Cabral D, Prendiville JS, Stringer D, Petty RE, Malleson PN (1997) Intestinal pseudo-obstruction as an initial presentation of systemic sclerosis in two children. Br J Rheumatol 36:280\u2013284","journal-title":"Br J Rheumatol"},{"key":"8969_CR214","doi-asserted-by":"crossref","unstructured":"Vigone B, Beretta L (2019) Abatacept to treat chronic intestinal pseudo-obstruction in five systemic sclerosis patients with a description of the index case. J Scleroderma Relat Disord 4:NP5\u2013NP9","DOI":"10.1177\/2397198318766819"},{"key":"8969_CR215","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/rheumatology\/kev318","volume":"55","author":"J Raja","year":"2016","unstructured":"Raja J, Nihtyanova SI, Murray CD, Denton CP, Ong VH (2016) Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatology (Oxford) 55:115\u2013119","journal-title":"Rheumatology (Oxford)"},{"key":"8969_CR216","first-page":"S168","volume":"33","author":"KEN Clark","year":"2015","unstructured":"Clark KEN, Etomi O, Denton CP, Ong VH, Murray CD (2015) Intravenous immunogobulin therapy for severe gastrointestinal involvement in systemic sclerosis. Clin Exp Rheumatol 33:S168-170","journal-title":"Clin Exp Rheumatol"},{"key":"8969_CR217","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-022-05264-4","author":"V Hamberg","year":"2022","unstructured":"Hamberg V, Wallman JK, Mogard E, Lindqvist E, Olofsson T, Andr\u00e9asson K (2022) Elevated fecal levels of the inflammatory biomarker calprotectin in early systemic sclerosis. Rheumatol Int. https:\/\/doi.org\/10.1007\/s00296-022-05264-4","journal-title":"Rheumatol Int"},{"key":"8969_CR218","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMra0806188","volume":"360","author":"A Gabrielli","year":"2009","unstructured":"Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360:1989\u20132003","journal-title":"N Engl J Med"},{"issue":"22","key":"8969_CR219","first-page":"01692","volume":"S0140\u20136736","author":"ER Volkmann","year":"2022","unstructured":"Volkmann ER, Andr\u00e9asson K, Smith V (2022) Systemic sclerosis. Lancet S0140\u20136736(22):01692","journal-title":"Lancet"},{"key":"8969_CR220","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1093\/rheumatology\/keac188","volume":"61","author":"E Zanatta","year":"2022","unstructured":"Zanatta E, Huscher D, Ortolan A et al (2022) Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. Rheumatology (Oxford) 61:4786\u20134796","journal-title":"Rheumatology (Oxford)"},{"key":"8969_CR221","doi-asserted-by":"crossref","unstructured":"Hughes M, Huang S, Alegre-Sancho JJ, et al (2022) Late skin fibrosis in systemic sclerosis: a study from the EUSTAR cohort. Rheumatology (Oxford) keac363","DOI":"10.1136\/annrheumdis-2022-eular.4227"},{"key":"8969_CR222","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/qjmed\/hcab331","volume":"115","author":"T Horino","year":"2022","unstructured":"Horino T, Inotani S, Nakajima H, Ohnishi H, Komori M, Terada Y (2022) Calcinosis and acro-osteolysis in systemic sclerosis. QJM 115:113\u2013114","journal-title":"QJM"},{"key":"8969_CR223","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jaad.2018.07.033","volume":"80","author":"V Leroy","year":"2019","unstructured":"Leroy V, Henrot P, Barnetche T et al (2019) Association of skin hyperpigmentation disorders with digital ulcers in systemic sclerosis: analysis of a cohort of 239 patients. J Am Acad Dermatol 80:478\u2013484","journal-title":"J Am Acad Dermatol"},{"key":"8969_CR224","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002890","volume":"9","author":"R De Angelis","year":"2023","unstructured":"De Angelis R, Ferri C, Giuggioli D et al (2023) Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry \u201cSPRING\u201d of the Italian Society for Rheumatology. RMD Open 9:e002890","journal-title":"RMD Open"},{"key":"8969_CR225","first-page":"47","volume":"17","author":"M De Santis","year":"2015","unstructured":"De Santis M, Selmi C (2015) The autoinflammatory side of systemic sclerosis. Isr Med Assoc J 17:47\u201349","journal-title":"Isr Med Assoc J"},{"key":"8969_CR226","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13075-022-02889-5","volume":"24","author":"C Lin","year":"2022","unstructured":"Lin C, Jiang Z, Cao L, Zou H, Zhu X (2022) Role of NLRP3 inflammasome in systemic sclerosis. Arthritis Res Ther 24:196","journal-title":"Arthritis Res Ther"},{"key":"8969_CR227","first-page":"5","volume":"17","author":"MA Mart\u00ednez-God\u00ednez","year":"2015","unstructured":"Mart\u00ednez-God\u00ednez MA, Cruz-Dom\u00ednguez MP, Jara LJ et al (2015) Expression of NLRP3 inflammasome, cytokines and vascular mediators in the skin of systemic sclerosis patients. Isr Med Assoc J 17:5\u201310","journal-title":"Isr Med Assoc J"},{"key":"8969_CR228","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1165\/rcmb.2008-0182OC","volume":"41","author":"T Hoshino","year":"2009","unstructured":"Hoshino T, Okamoto M, Sakazaki Y, Kato S, Young HA, Aizawa H (2009) Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice. Am J Respir Cell Mol Biol 41:661\u2013670","journal-title":"Am J Respir Cell Mol Biol"},{"key":"8969_CR229","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1002\/art.30568","volume":"63","author":"CM Artlett","year":"2011","unstructured":"Artlett CM, Sassi-Gaha S, Rieger JL, Boesteanu AC, Feghali-Bostwick CA, Katsikis PD (2011) The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum 63:3563\u20133574","journal-title":"Arthritis Rheum"},{"key":"8969_CR230","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.3389\/fimmu.2019.02025","volume":"10","author":"D Xu","year":"2019","unstructured":"Xu D, Mu R, Wei X (2019) The roles of IL-1 family cytokines in the pathogenesis of systemic sclerosis. Front Immunol 10:2025","journal-title":"Front Immunol"},{"key":"8969_CR231","unstructured":"Mantero JC, Kishore N, Ziemek J, et al (2018) Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I\/II biomarker trial. Clin Exp Rheumatol 36 Suppl 113:146\u2013149"},{"key":"8969_CR232","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/cei.13599","volume":"205","author":"P Di Benedetto","year":"2021","unstructured":"Di Benedetto P, Ruscitti P, Berardicurti O, Vomero M, Navarini L, Dolo V, Cipriani P, Giacomelli R (2021) Endothelial-to-mesenchymal transition in systemic sclerosis. Clin Exp Immunol 205:12\u201327","journal-title":"Clin Exp Immunol"},{"key":"8969_CR233","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3389\/fimmu.2018.02452","volume":"9","author":"A van Caam","year":"2018","unstructured":"van Caam A, Vonk M, van den Hoogen F, van Lent P, van der Kraan P (2018) Unraveling SSc pathophysiology; the myofibroblast. Front Immunol 9:2452","journal-title":"Front Immunol"},{"key":"8969_CR234","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1136\/annrheumdis-2011-200955","volume":"71","author":"K Khan","year":"2012","unstructured":"Khan K, Xu S, Nihtyanova S, Derrett-Smith E, Abraham D, Denton CP, Ong VH (2012) Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis 71:1235\u20131242","journal-title":"Ann Rheum Dis"},{"key":"8969_CR235","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ajpath.2011.09.013","volume":"180","author":"S Kitaba","year":"2012","unstructured":"Kitaba S, Murota H, Terao M et al (2012) Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 180:165\u2013176","journal-title":"Am J Pathol"},{"key":"8969_CR236","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.3390\/cells10051104","volume":"10","author":"Y Shima","year":"2021","unstructured":"Shima Y (2021) Cytokines involved in the pathogenesis of SSc and problems in the development of anti-cytokine therapy. Cells 10:1104","journal-title":"Cells"},{"key":"8969_CR237","doi-asserted-by":"publisher","first-page":"R54","DOI":"10.1186\/ar2965","volume":"12","author":"S Bosello","year":"2010","unstructured":"Bosello S, De Santis M, Lama G, Span\u00f2 C, Angelucci C, Tolusso B, Sica G, Ferraccioli G (2010) B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 12:R54","journal-title":"Arthritis Res Ther"},{"key":"8969_CR238","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.933468","volume":"13","author":"B Thoreau","year":"2022","unstructured":"Thoreau B, Chaigne B, Mouthon L (2022) Role of B-cell in the pathogenesis of systemic sclerosis. Front Immunol 13:933468","journal-title":"Front Immunol"},{"key":"8969_CR239","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41584-022-00864-7","volume":"18","author":"D Fang","year":"2022","unstructured":"Fang D, Chen B, Lescoat A, Khanna D, Mu R (2022) Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis. Nat Rev Rheumatol 18:683\u2013693","journal-title":"Nat Rev Rheumatol"},{"key":"8969_CR240","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/art.40358","volume":"70","author":"JK Gordon","year":"2018","unstructured":"Gordon JK, Martyanov V, Franks JM, Bernstein EJ, Szymonifka J, Magro C, Wildman HF, Wood TA, Whitfield ML, Spiera RF (2018) Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial. Arthritis Rheumatol 70:308\u2013316","journal-title":"Arthritis Rheumatol"},{"key":"8969_CR241","doi-asserted-by":"publisher","first-page":"R4","DOI":"10.1186\/ar4430","volume":"16","author":"X Yang","year":"2014","unstructured":"Yang X, Yang J, Xing X, Wan L, Li M (2014) Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction. Arthritis Res Ther 16:R4","journal-title":"Arthritis Res Ther"},{"key":"8969_CR242","doi-asserted-by":"publisher","first-page":"13600","DOI":"10.1111\/jcmm.15266","volume":"24","author":"X Xing","year":"2020","unstructured":"Xing X, Li A, Tan H, Zhou Y (2020) IFN-\u03b3+ IL-17+ Th17 cells regulate fibrosis through secreting IL-21 in systemic scleroderma. J Cell Mol Med 24:13600\u201313608","journal-title":"J Cell Mol Med"},{"key":"8969_CR243","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.3389\/fimmu.2018.01611","volume":"9","author":"M-J Park","year":"2018","unstructured":"Park M-J, Moon S-J, Lee E-J et al (2018) IL-1-IL-17 signaling axis contributes to fibrosis and inflammation in two different murine models of systemic sclerosis. Front Immunol 9:1611","journal-title":"Front Immunol"},{"issue":"Suppl 100","key":"8969_CR244","first-page":"14","volume":"34","author":"L Lei","year":"2016","unstructured":"Lei L, Zhao C, Qin F, He Z-Y, Wang X, Zhong X-N (2016) Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis. Clin Exp Rheumatol 34(Suppl 100):14\u201322","journal-title":"Clin Exp Rheumatol"},{"key":"8969_CR245","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.885609","volume":"13","author":"L Wei","year":"2022","unstructured":"Wei L, Abraham D, Ong V (2022) The Yin and Yang of IL-17 in systemic sclerosis. Front Immunol 13:885609","journal-title":"Front Immunol"},{"key":"8969_CR246","doi-asserted-by":"publisher","first-page":"R10","DOI":"10.1186\/ar1860","volume":"8","author":"C Chizzolini","year":"2006","unstructured":"Chizzolini C, Parel Y, Scheja A, Dayer J-M (2006) Polarized subsets of human T-helper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblasts. Arthritis Res Ther 8:R10","journal-title":"Arthritis Res Ther"},{"key":"8969_CR247","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103185","volume":"21","author":"W Jin","year":"2022","unstructured":"Jin W, Zheng Y, Zhu P (2022) T cell abnormalities in systemic sclerosis. Autoimmun Rev 21:103185","journal-title":"Autoimmun Rev"},{"key":"8969_CR248","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/annrheumdis-2019-215894","volume":"79","author":"B Skaug","year":"2020","unstructured":"Skaug B, Khanna D, Swindell WR et al (2020) Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Ann Rheum Dis 79:379\u2013386","journal-title":"Ann Rheum Dis"},{"key":"8969_CR249","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/art.41243","volume":"72","author":"R Bhandari","year":"2020","unstructured":"Bhandari R, Ball MS, Martyanov V et al (2020) Profibrotic activation of human macrophages in systemic sclerosis. Arthritis Rheumatol 72:1160\u20131169","journal-title":"Arthritis Rheumatol"},{"key":"8969_CR250","doi-asserted-by":"publisher","first-page":"8509583","DOI":"10.1155\/2018\/8509583","volume":"2018","author":"C Frantz","year":"2018","unstructured":"Frantz C, Pezet S, Avouac J, Allanore Y (2018) Soluble CD163 as a potential biomarker in systemic sclerosis. Dis Markers 2018:8509583","journal-title":"Dis Markers"},{"key":"8969_CR251","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/path.5680","volume":"254","author":"EH Budi","year":"2021","unstructured":"Budi EH, Schaub JR, Decaris M, Turner S, Derynck R (2021) TGF -\u03b2 as a driver of fibrosis: physiological roles and therapeutic opportunities. J Pathol 254:358\u2013373","journal-title":"J Pathol"},{"key":"8969_CR252","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1172\/JCI77958","volume":"125","author":"LM Rice","year":"2015","unstructured":"Rice LM, Padilla CM, McLaughlin SR et al (2015) Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 125:2795\u20132807","journal-title":"J Clin Invest"},{"key":"8969_CR253","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jaci.2017.10.029","volume":"142","author":"S Cascio","year":"2018","unstructured":"Cascio S, Medsger TA, Hawse WF, Watkins SC, Milcarek C, Moreland LW, Lafyatis RA, Fuschiotti P (2018) 14-3-3z sequesters cytosolic T-bet, upregulating IL-13 levels in TC2 and CD8+ lymphocytes from patients with scleroderma. J Allergy Clin Immunol 142:109-119.e6","journal-title":"J Allergy Clin Immunol"},{"key":"8969_CR254","first-page":"328","volume":"24","author":"M Hasegawa","year":"1997","unstructured":"Hasegawa M, Fujimoto M, Kikuchi K, Takehara K (1997) Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 24:328\u2013332","journal-title":"J Rheumatol"},{"key":"8969_CR255","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1097\/BOR.0000000000000553","volume":"30","author":"P Fuschiotti","year":"2018","unstructured":"Fuschiotti P (2018) T cells and cytokines in systemic sclerosis. Curr Opin Rheumatol 30:594\u2013599","journal-title":"Curr Opin Rheumatol"},{"key":"8969_CR256","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1067\/mai.2001.114702","volume":"107","author":"S Hashimoto","year":"2001","unstructured":"Hashimoto S, Gon Y, Takeshita I, Maruoka S, Horie T (2001) IL-4 and IL-13 induce myofibroblastic phenotype of human lung fibroblasts through c-Jun NH2-terminal kinase\u2013dependent pathway. Journal of Allergy and Clinical Immunology 107:1001\u20131008","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"8969_CR257","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1136\/annrheumdis-2020-218447","volume":"79","author":"Y Allanore","year":"2020","unstructured":"Allanore Y, Wung P, Soubrane C, Esperet C, Marrache F, Bejuit R, Lahmar A, Khanna D, Denton CP (2020) A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis 79:1600\u20131607","journal-title":"Ann Rheum Dis"},{"key":"8969_CR258","doi-asserted-by":"crossref","unstructured":"Riemekasten G, Distler JHW (2022) A broad look into the future of systemic sclerosis. Ther Adv Musculoskelet Dis 14:1759720X221109404","DOI":"10.1177\/1759720X221109404"},{"key":"8969_CR259","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102526","volume":"113","author":"JC Worrell","year":"2020","unstructured":"Worrell JC, O\u2019Reilly S (2020) Bi-directional communication: conversations between fibroblasts and immune cells in systemic sclerosis. J Autoimmun 113:102526","journal-title":"J Autoimmun"},{"key":"8969_CR260","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1038\/s41467-021-24607-6","volume":"12","author":"T Tabib","year":"2021","unstructured":"Tabib T, Huang M, Morse N et al (2021) Myofibroblast transcriptome indicates SFRP2hi fibroblast progenitors in systemic sclerosis skin. Nat Commun 12:4384","journal-title":"Nat Commun"},{"key":"8969_CR261","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41590-022-01294-z","volume":"23","author":"C Ospelt","year":"2022","unstructured":"Ospelt C (2022) A common activator of tissue-remodeling fibroblasts across tissues. Nat Immunol 23:1295\u20131296","journal-title":"Nat Immunol"},{"key":"8969_CR262","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41586-019-0896-x","volume":"566","author":"T Wohlfahrt","year":"2019","unstructured":"Wohlfahrt T, Rauber S, Uebe S et al (2019) PU.1 controls fibroblast polarization and tissue fibrosis. Nature 566:344\u2013349","journal-title":"Nature"},{"key":"8969_CR263","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41584-022-00858-5","volume":"18","author":"R Phillips","year":"2022","unstructured":"Phillips R (2022) Thy-1 promotes skin fibrosis in SSc. Nat Rev Rheumatol 18:613","journal-title":"Nat Rev Rheumatol"},{"key":"8969_CR264","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.149426","volume":"7","author":"RG Marangoni","year":"2022","unstructured":"Marangoni RG, Datta P, Paine A, Duemmel S, Nuzzo M, Sherwood L, Varga J, Ritchlin C, Korman BD (2022) Thy-1 plays a pathogenic role and is a potential biomarker for skin fibrosis in scleroderma. JCI Insight 7:e149426","journal-title":"JCI Insight"},{"key":"8969_CR265","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M et al (2019) Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 380:2518\u20132528","journal-title":"N Engl J Med"},{"key":"8969_CR266","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/art.41813","volume":"74","author":"D Xue","year":"2022","unstructured":"Xue D, Tabib T, Morse C, Yang Y, Domsic RT, Khanna D, Lafyatis R (2022) Expansion of Fc\u03b3 receptor IIIa-positive macrophages, ficolin 1-positive monocyte-derived dendritic cells, and plasmacytoid dendritic cells associated with severe skin disease in systemic sclerosis. Arthritis Rheumatol 74:329\u2013341","journal-title":"Arthritis Rheumatol"},{"key":"8969_CR267","doi-asserted-by":"crossref","unstructured":"Papazoglou A, Huang M, Bulik M, Lafyatis A, Tabib T, Morse C, Sembrat J, Rojas M, Valenzi E, Lafyatis R (2022) Epigenetic regulation of profibrotic macrophages in systemic sclerosis-associated interstitial lung disease. arthritis rheumatol 74:2003\u20132014","DOI":"10.1002\/art.42286"},{"key":"8969_CR268","doi-asserted-by":"publisher","first-page":"1802441","DOI":"10.1183\/13993003.02441-2018","volume":"54","author":"C Morse","year":"2019","unstructured":"Morse C, Tabib T, Sembrat J et al (2019) Proliferating SPP1\/MERTK-expressing macrophages in idiopathic pulmonary fibrosis. Eur Respir J 54:1802441","journal-title":"Eur Respir J"},{"key":"8969_CR269","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/rheumatology\/kes041","volume":"51","author":"J Avouac","year":"2012","unstructured":"Avouac J, Clements PJ, Khanna D, Furst DE, Allanore Y (2012) Articular involvement in systemic sclerosis Rheumatology (Oxford) 51:1347\u20131356","journal-title":"Articular involvement in systemic sclerosis Rheumatology (Oxford)"},{"key":"8969_CR270","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.3899\/jrheum.091165","volume":"37","author":"J Avouac","year":"2010","unstructured":"Avouac J, Walker U, Tyndall A et al (2010) Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol 37:1488\u20131501","journal-title":"J Rheumatol"},{"key":"8969_CR271","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1136\/ard.2005.044602","volume":"65","author":"J Avouac","year":"2006","unstructured":"Avouac J, Guerini H, Wipff J, Assous N, Chevrot A, Kahan A, Allanore Y (2006) Radiological hand involvement in systemic sclerosis. Ann Rheum Dis 65:1088\u20131092","journal-title":"Ann Rheum Dis"},{"key":"8969_CR272","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1136\/ard.2006.051391","volume":"65","author":"J Avouac","year":"2006","unstructured":"Avouac J, Gossec L, Dougados M (2006) Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 65:845\u2013851","journal-title":"Ann Rheum Dis"},{"key":"8969_CR273","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/rheumatology\/kep138","volume":"48","author":"S Generini","year":"2009","unstructured":"Generini S, Steiner G, Miniati I, Conforti ML, Guiducci S, Skriner K, Kaloudi O, Giacomelli R, Smolen J, Matucci-Cerinic M (2009) Anti-hnRNP and other autoantibodies in systemic sclerosis with joint involvement. Rheumatology (Oxford) 48:920\u2013925","journal-title":"Rheumatology (Oxford)"},{"key":"8969_CR274","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jbspin.2011.02.022","volume":"79","author":"TA Gheita","year":"2012","unstructured":"Gheita TA, Hussein H (2012) Cartilage oligomeric matrix protein (COMP) in systemic sclerosis (SSc): role in disease severity and subclinical rheumatoid arthritis overlap. Joint Bone Spine 79:51\u201356","journal-title":"Joint Bone Spine"},{"key":"8969_CR275","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s00296-019-04402-9","volume":"39","author":"R Karalilova","year":"2019","unstructured":"Karalilova R, Kazakova M, Sapundzhieva T, Dichev V, Batalov Z, Sarafian V, Batalov A (2019) Serum YKL-40 and IL-6 levels correlate with ultrasound findings of articular and periarticular involvement in patients with systemic sclerosis. Rheumatol Int 39:1841\u20131848","journal-title":"Rheumatol Int"},{"key":"8969_CR276","first-page":"172","volume":"53","author":"JS Johansen","year":"2006","unstructured":"Johansen JS (2006) Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53:172\u2013209","journal-title":"Dan Med Bull"},{"key":"8969_CR277","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1136\/annrheumdis-2018-213201","volume":"77","author":"W Wu","year":"2018","unstructured":"Wu W, Jordan S, Becker MO et al (2018) Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Ann Rheum Dis 77:1326\u20131332","journal-title":"Ann Rheum Dis"},{"key":"8969_CR278","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s10067-022-06367-w","volume":"42","author":"A Colalillo","year":"2023","unstructured":"Colalillo A, Pellicano C, Rosato E (2023) Serum-soluble ST2 and systemic sclerosis arthropathy. Clin Rheumatol 42:871\u2013877","journal-title":"Clin Rheumatol"},{"key":"8969_CR279","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41584-020-0491-4","volume":"16","author":"C Pitzalis","year":"2020","unstructured":"Pitzalis C, Choy EHS, Buch MH (2020) Transforming clinical trials in rheumatology: towards patient-centric precision medicine. Nat Rev Rheumatol 16:590\u2013599","journal-title":"Nat Rev Rheumatol"},{"key":"8969_CR280","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103261","volume":"22","author":"B Chaigne","year":"2023","unstructured":"Chaigne B, L\u00e9onard-Louis S, Mouthon L (2023) Systemic sclerosis associated myopathy. Autoimmun Rev 22:103261","journal-title":"Autoimmun Rev"},{"key":"8969_CR281","doi-asserted-by":"crossref","unstructured":"Matas-Garc\u00eda A, Guill\u00e9n-Del-Castillo A, Kisluk B et al (2023) Clinico-pathological phenotypes of systemic sclerosis-associated myopathy: analysis of a large multicentre cohort. Rheumatology (Oxford) 62:SI82\u2013SI90","DOI":"10.1093\/rheumatology\/keac361"},{"key":"8969_CR282","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3109\/03009742.2013.868512","volume":"43","author":"Jung M, Bonner A, Hudson M, Baron M, Pope JE, Canadian Scleroderma Research Group (CSRG)","year":"2014","unstructured":"Jung M, Bonner A, Hudson M, Baron M, Pope JE, Canadian Scleroderma Research Group (CSRG) (2014) Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort. Scand J Rheumatol 43:217\u2013220","journal-title":"Scand J Rheumatol"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-023-08969-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-023-08969-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-023-08969-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T11:26:26Z","timestamp":1702985186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-023-08969-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":282,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["8969"],"URL":"https:\/\/doi.org\/10.1007\/s12016-023-08969-x","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,21]]},"assertion":[{"value":"30 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}